Tin tức & Cập nhật
Xem bài viết Gan
Xem
Chỉ hiển thị Multimedia

PARG inhibition slows HCC progression, boosts efficacy of immune checkpoint therapy
05 Jul 2022
In hepatocellular carcinoma (HCC), poly(ADP-ribose) glycohydrolase (PARG) may serve as an oncogene by modulating PARG/DDB1/c-Myc signaling and be used as a biomarker to identify HCC patients who may derive benefit from anti-PD-1 treatment, suggests a study.
05 Jul 2022







